Asai, D. and T. Imamura, et al. (2013). "IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan." Cancer Med 2 (3): 412-9.
Caye, A. and K. Beldjord, et al. (2013). "Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia." Haematologica 98 (4): 597-601.
Cui, L. and Z. G. Li, et al. (2018). "Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China." Am J Hematol 93 (7): 913-920.
Dorge, P. and B. Meissner, et al. (2013). "IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol." Haematologica 98 (3): 428-32.
Enshaei, A. and C. J. Schwab, et al. (2013). "Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor." Leukemia 27 (11): 2256-9.
Iacobucci, I. and C. G. Mullighan (2017). "Genetic Basis of Acute Lymphoblastic Leukemia." J Clin Oncol 35 (9): 975-983.
Lilljebjorn, H. and R. Henningsson, et al. (2016). "Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia." Nat Commun 7: 11790.
Linda Olsson, B. J. (2015). "Ikaros and leukaemia." Br J Haematol 169 (4): 479-491.
Li-Xin Wu, J. Z. Q. Y. (2017). "High frequency of IKZF1 deletions in Chinese adult patients with acute lymphoblastic leukemia detected by multiplex realtime quantitative PCR." Clinical and Diagnostic Pathology 1 (2): 1-7.
Mullighan, C. G. (2012). "The molecular genetic makeup of acute lymphoblastic leukemia." Hematology Am Soc Hematol Educ Program 2012: 389-96.
Mullighan, C. G. and C. B. Miller, et al. (2008). "BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros." Nature 453 (7191): 110-4.
Mullighan, C. G. and X. Su, et al. (2009). "Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia." N Engl J Med 360 (5): 470-80.
Olsson, L. and A. Castor, et al. (2014). "Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011." Leukemia 28 (2): 302-10.
Olsson, L. and O. I. Ivanov, et al. (2015). "The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013." Br J Haematol 170 (6): 847-58.
Palmi, C. and M. G. Valsecchi, et al. (2013). "What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?" Haematologica 98 (8): 1226-31.
Payne, M. A. (2011). "Zinc finger structure-function in Ikaros Marvin A Payne." World J Biol Chem 2 (6): 161-6.
Pui, C. H. and D. Pei, et al. (2014). "A revised definition for cure of childhood acute lymphoblastic leukemia." Leukemia 28 (12): 2336-43.
Slayton, W. B. and K. R. Schultz, et al. (2018). "Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622." J Clin Oncol 36 (22): 2306-2314.
Stanulla, M. and H. Cave, et al. (2020). "IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?" Blood 135 (4): 252-260.
Vairy, S. and T. H. Tran (2020). "IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly." Blood Rev 44: 100677.
van der Veer, A. and E. Waanders, et al. (2013). "Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL." Blood 122 (15): 2622-9.
van der Veer, A. and M. Zaliova, et al. (2014). "IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL." Blood 123 (11): 1691-8.
Venn, N. C. and V. H. van der Velden, et al. (2012). "Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion." Leukemia 26 (6): 1414-6.
Wang, Y. and H. M. Zeng, et al. (2018). "ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol." Ital J Pediatr 44 (1): 94.
Winick, N. and M. Devidas, et al. (2017). "Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group." J Clin Oncol 35 (22): 2527-2534.
Xue, Y. J. and Y. F. Cheng, et al. (2019). "Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era." Biol Blood Marrow Transplant 25 (8): 1611-1620.